Your browser doesn't support javascript.
loading
[Ratio of Primary Bone Marrow Cells after Induction Chemothrapy for Two Weeks in the Patients with Ph- ALL and Its Influence on Complete Remission and Overall Progrosis].
Wu, Xi-Feng; Sun, Ling; Li, Tan-Tan; Yin, Xiang-Cong; Ran, Xue-Hong.
Affiliation
  • Wu XF; Department of Hematology, Laiwu Hospital Affiliated to Taishan Medical College, Laiwu 271100, Shandong Province, China.
  • Sun L; Department of Hematology, Laiwu Hospital Affiliated to Taishan Medical College, Laiwu 271100, Shandong Province, China.
  • Li TT; Department of Hematology, Laiwu Hospital Affiliated to Taishan Medical College, Laiwu 271100, Shandong Province, China.
  • Yin XC; Laboratory of Hematology, Affiliated Hospital of Qingdao University, Qingdao 266003, Shandong Province, China.
  • Ran XH; Department of Hematology, Weifang People's Hospital, Weifang 261041, Shandong Province, China. E-mail: ggtgyx1@126.com.
Zhongguo Shi Yan Xue Ye Xue Za Zhi ; 25(3): 749-753, 2017 Jun.
Article in Zh | MEDLINE | ID: mdl-28641629
OBJECTIVE: To investigate the influence of bone marrow blasts ratio after induction chemotherapy for 2 weeks in patients with Ph- ALL, and it's influence on complete remission (CR) and overall prognosis. METHODS: A total of 172 patients with Ph- ALL in our hospital from March 2012 to February 2016 were selected. The bone marrow blast ratio was analyzed by the receiver-operating characteristic curve (ROC) in patients after induction chemotherapy for 2 weeks, at same time its influence on CR and overall prognosis of Ph- ALL patients was evaluated. RESULTS: The cutoff value of CR was 0.075, its area under ROC was 0.763; the comparison of area under ROC with Az=0.5 showed statistically significant difference, therefore 172 patients with Ph- ALL were grouped according to bone marrow blast ratio after induction chemotherapy for 2 weeks: 104 cases (60.5%) with bone marrow blast ratio <0.075, 68 cases (39.5%) with bone marrow blast ratio ≥0.075. The Ph- ALL patinets with bone marrow blast ratio <0.075 who achieved CR and finally achieved CR after induction chemotherapy for 4 weeks acconnted for 89 (85.6%) and 99(95.2%) respectively, which were significantly higher than those in Ph- ALL patients with bone marrow blast ratio≥0.075, [29(42.6%) and 52 (76.5%)](P<0.05). In addition, the influencing factor clinically reducing the OS and DFS rate of patients and enhancing the ralapse rate of patients were mainly chemotherapy, the failure of induction chemotherapy (patients did not achieve CR after induction therapy for 4 weeks), the bone marrow blast ratio≥0.075 after induction treatment for 2 weeks, and CNSL at diagnosis and so on, while the enhaced WBC count at diagnosis was poor factor affecting the DFS rate of patients. CONCLUSION: After induction chemotherapy for 2 weeks, the elevated bone marrow blast ratio in Ph- ALL patients will be infavourable to CR, and the overall prognosis is poor.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Bone Marrow Cells / Antineoplastic Combined Chemotherapy Protocols / Precursor Cell Lymphoblastic Leukemia-Lymphoma / Induction Chemotherapy Type of study: Prognostic_studies Limits: Humans Language: Zh Journal: Zhongguo Shi Yan Xue Ye Xue Za Zhi Journal subject: HEMATOLOGIA Year: 2017 Document type: Article Affiliation country: China Country of publication: China

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Bone Marrow Cells / Antineoplastic Combined Chemotherapy Protocols / Precursor Cell Lymphoblastic Leukemia-Lymphoma / Induction Chemotherapy Type of study: Prognostic_studies Limits: Humans Language: Zh Journal: Zhongguo Shi Yan Xue Ye Xue Za Zhi Journal subject: HEMATOLOGIA Year: 2017 Document type: Article Affiliation country: China Country of publication: China